SEC Form 4 · accession 0001209191-17-056187
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J Garrity
Director
Period of report
Oct 3, 2017
Accepted (ET)
Oct 5, 2017 · 5:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 3, 2017 | M | 30,000 | $0.85 | A | 190,213 | D | |
| Common Stock | Oct 3, 2017 | S | 30,000 | $3.50 | D | 160,213 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.85 | Oct 3, 2017 | M | 30,000 | D | — | May 13, 2018 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted in September 2016.
- F2The options vested and became exercisable in four equal quarterly installments following the grant date of May 14, 2008.